Amna Parvez

Amna Parvez

Auto-generated profile, based on publicly available information

Amna Parvez

Department of Internal Medicine, Dow Medical College, Karachi, Pakistan, duhs.edu.pk

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2025 in Journal of the Pakistan Medical Association
Verified
Journal Article
Open access
PDF file
APAmna Parvez
Amna Parvez
MAMehreen Ansari
Mehreen Ansari
In recent literature, a Spanish study defines ‘difficult’ laparoscopic cholecystectomy (DLC) as the presence of at least one of the following conditions in an intraoperative setting: bile duct injury, Mirizzi syndrome, Calot triangle inflammation, conversion to laparotomy, and pericholecystic abscess.1 The standardisation of a criteria is important to provide scores that could predict difficulty preoperatively and have lasting implications on surgical safety and postoperative patient recovery. The 2020 World Society of Emergency Surgery (WSES) guidelines for the management of bile duct injury during cholecystectomy recommend a thorough preoperative work-up to detect at-risk patients, signifying the need for a preoperative assessment scale.2 Clinically, there are numerous predictive assessment scores in practice globally, each specific to a certain demographic, unique in limitations and employing diverse clinical, laboratory and radiological parameters. Currently, use of predictive assessment scores for DLC is not a common practice in Pakistan, however, studies have determined advanced age, obesity, previous abdominal surgery, deranged alkaline phosphatase (ALP) and multiple stones, as potential risk factors in our population. A value of C reactive protein(CRP) greater than 11 mg/dl was identified as having good sensitivity and specificity for predicting DLC in Pakistan.3 Concurrently, male gender was concluded to be an independent risk factor for DLC (P = 0.041) on account of more adhesions and inflammation.4 This data offers unique insight into our population, and can become grounds for establishing a novel standard predictive score for clinical use in Pakistan. A score by Randhawa et al could be our foundation due to similar demographics and identified potential risk factors of our population could be incorporated in a new scoring method.5 In a developing country like Pakistan, a standard score for this relatively common surgical procedure could prove pivotal in resource management. Better selection of out-patient procedures and targeted surgical planning can save money, manpower and equipment. This approach will allow better preoperative counselling regarding prognosis and aid in undertaking informed consent. Identification and hands-on training of low risk procedures could be pivotal for our residency training programs. Further randomised prospective studies with large sample size are required to determine an efficient scoring system for the Pakistani population. However, any study which attempts to do so should keep in mind the limited resources in various hospitals across pakistan. A generalised scale that relies more on clinical parameters and accessible lab markers and less on expensive radiology and high expertise should be preferred.

14 January 2026 in Cardiovascular Therapeutics
Verified
Journal Article
Open access
KFKainat Feroz
Kainat Feroz
APAmna Parvez
Amna Parvez
NRNoor Ul Huda Ramzan
Noor Ul Huda Ramzan
TATehreem Asghar
Tehreem Asghar
ACAmeer Haider Cheema
Ameer Haider Cheema
BSBrijesh Sathian
Brijesh Sathian
Aims: Novel drugs that target apoC‐III in lipoprotein metabolism to reduce plasma triglycerides are currently under development. Olezarsen, a drug similar to its predecessor, volanesorsen, is in Phase 3 trials. A meta‐analysis of RCTs was done to study its effect on hypertriglyceridemia. Material and Methods: Screening was done on PubMed, Embase, Scopus, and the Cochrane Library from inception to August 2024. We used Review Manager (Version 5.4) for statistical analysis. Subgroups of olezarsen at doses of 10, 50, and 80 mg were made. Continuous outcomes were reported as mean differences with 95% CIs. Adverse events were reported using risk ratios and 95% CIs. The risk of bias was analyzed using the Cochrane risk of bias tool. Results: Four RCTs with 374 participants, 278 in intervention and 96 placebo controls, were included. At all doses of olezarsen, a significant reduction in fasting triglyceride levels (MD: 45.69; 95% CI: 35.84, 55.54; p < 0.00001) was seen. This was most pronounced at 80 mg dose (MD: 51.98 95% CI: 43.06, 60.90; p < 0.00001). A reduction in apoC‐III (MD: 58.77; 95% CI: 35.94, 81.61; p < 0.00001) and an increase in HDL (MD: 0.21; 95% CI: 0.04, 0.37; p = 0.01) were also observed. No significant effect was observed on LDL levels (MD: −0.13; 95% CI: −0.40, 0.14; p = 0.34). Overall, no significant adverse effects were seen compared to placebo (RR: 1.42; 95% CI: 0.66, 3.05; p = 0.37). Conclusion: Olezarsen showed remarkable efficacy in lowering triglycerides, with a dose‐dependent effect, while significantly increasing HDL levels and reducing apoC‐III. Its safety profile is commendable. Although it performed well compared to volanesorsen, inconsistencies in LDL reduction and heterogeneity in some groups warrant further large‐scale RCTs to better assess its safety and efficacy. Clinical decisions should be tailored to individual patient profiles, as hypertriglyceridemia management may vary on a case‐to‐case basis.

8 October 2026 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
VDVishan Das
Vishan Das
APAmna Parvez
Amna Parvez
Sadia QaziSadia Qazi
Sadia Qazi
KFKaneez Fatima
Kaneez Fatima
MMMuhammad Mukhlis
Muhammad Mukhlis
MKMuhammad Hanif Khan
Muhammad Hanif Khan
Introduction: Chronic lower respiratory disease (CLRD) and dementia are the leading causes of death among older US adults and frequently coexist; however, their combined mortality burden is uncharacterized nationally. We examined the trends and disparities in deaths involving both. Methods: We analyzed 1999–2023 US multiple cause-of-death data from the CDC WONDER for decedents aged ≥ 65 years with both CLRD (ICD-10 J40–J47) and dementia (F01, F03, G30–G31) listed anywhere on the certificate. Age-adjusted mortality rates (AAMRs) per 100,000 were calculated overall and by sex, race/ethnicity, census region, urbanization, and place of death; crude rates (CMRs) were used for age strata. Joinpoint regression gave annual and average annual percent changes (APCs, AAPCs). Results: Among 557,547 deaths, the overall AAMR rose from 29.50 per 100,000 in 1999 to 55.69 in 2023, peaking at 65.70 in 2020 (AAPC: 2.64; 95% CI: 0.93–4.39; p = 0.002). Men had a higher mean AAMR than women (57.58 vs. 47.29), but only women rose significantly (AAPC: 3.66; p < 0.001 vs. 1.42; p = 0.128); the male-to-female ratio fell from 1.62 to 0.97, with women overtaking men by 2023. The mean AAMRs were 55.07 in non-Hispanic (NH) White (AAPC: 3.02; p = 0.0004), 40.56 in NH Black (2.70; p = 0.035), 32.47 in Hispanic (1.20; p = 0.001), and 20.42 in NH Asian or Pacific Islander adults (3.13; p = 0.206); and 55.18 in the South (2.80; p < 0.001), 54.84 in the Midwest (3.02; p = 0.004), 51.19 in the West (2.53; p = 0.005), and 39.60 in the Northeast (1.91; p = 0.065). Non-metropolitan AAMRs exceeded metropolitan AAMRs (61.70 vs. 47.61; AAPC: 4.12; p < 0.001 vs. 2.85; p = 0.008), with the gap widening from 5.0 to 22.6. 2023 CMRs were 243.83 (≥ 85 years; AAPC: 3.19; p = 0.001), 59.36 (75–84; 2.38; p = 0.011) and 8.98 (65–74; 2.80; p = 0.019). Nursing home deaths fell from 58.2% to 43.3% as home deaths rose to 28.0% and hospice deaths to 7.9%. Conclusion: Mortality involving coexisting CLRD and dementia in older US adults nearly doubled from 1999 to 2023, shifting toward women, non-metropolitan residents, and the very old, while end-of-life care moved from hospitals and nursing homes into homes and hospices.